| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | SVP, Chief Medical Officer | Stock Options (Right to buy) | 17.4K | $448K | $25.84 | Feb 2, 2022 | Direct |
| Syndax Pharmaceuticals Inc | SVP, Chief Medical Officer | Common Stock | 23.3K | $425K | $18.27 | Jan 31, 2022 | Direct |
| Nuvalent, Inc. | Director | Class A Common Stock | 2.5K | $206K | $82.33 | Jun 12, 2024 | Direct |
| Nuvalent, Inc. | Director | Stock Option (Right to Buy) | 3.79K | Jun 12, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| NUVL | Nuvalent, Inc. | Jun 12, 2024 | 2 | $0 | 4 | Jun 14, 2024 | Director |
| NUVL | Nuvalent, Inc. | Jun 15, 2023 | 1 | $0 | 4 | Jun 16, 2023 | Director |
| NUVL | Nuvalent, Inc. | Oct 4, 2022 | 1 | $0 | 4 | Oct 6, 2022 | Director |
| NUVL | Nuvalent, Inc. | Oct 4, 2022 | 0 | $0 | 3 | Oct 6, 2022 | Director |
| SNDX | Syndax Pharmaceuticals Inc | Feb 2, 2022 | 2 | $295K | 4 | Feb 3, 2022 | SVP, Chief Medical Officer |
| SNDX | Syndax Pharmaceuticals Inc | Dec 30, 2021 | 2 | $51.7K | 4 | Jan 3, 2022 | SVP, Chief Medical Officer |